The expression of Tnfrsf17 is associated with antibody magnitude following immunization with a live attenuated yellow fever vaccine, trivalent inactivated influenza vaccine and polysaccharide-protein conjugate vaccine for Neisseria meningitidis, and is a potential biomarker for predicting the antibody response at 2–3 months after vaccination [24–26]. This evidence concerns the gene TNFRSF17 and viral infectious disease.